Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice

Marie-Rose B. S. Crombag,Aurelia H. M. de Vries Schultink,Jacobine G.C. van Doremalen,Hans-Martin Otten,Andries M. Bergman,Jan H. M. Schellens,Jos H. Beijnen,Alwin D. R. Huitema

Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice

2019

Marie-Rose B. S. Crombag
Aurelia H. M. de Vries Schultink
Jacobine G.C. van Doremalen
Hans-Martin Otten
Andries M. Bergman
Jan H. M. Schellens
Jos H. Beijnen
Alwin D. R. Huitema

Background Older patients with metastatic castration-resistant prostate cancer (mCRPC) may be more prone to chemotherapy-induced hematological toxicity, but tailored docetaxel dosing guidelines in older patients are lacking because of conflicting data.

Keywords:

Clinical Practice
Castration
Oncology
Diabetes mellitus
Dosing
Physical therapy
Prostate cancer
Toxicity
Internal medicine
Medicine
Docetaxel
Retrospective cohort study
Cancer
Pharmacotherapy
Quartile

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations